Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Frontdoor Inc (Symbol: FTDR), where a total of 2,600 contracts have traded so far, ...
Hosted on MSN
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. and Europe. The therapy has the potential to generate significant revenues, similar ...
View Arcturus Therapeutics Holdings, Inc. ARCT stock quote prices, financial information, real-time forecasts, and company news from CNN.
Arcturus Therapeutics (NASDAQ:ARCT) traded sharply lower on Friday after the company announced detailed results from a Phase 1b trial for ARCT-032, an experimental therapy for the lung disorder cystic ...
Arcturus Therapeutics (ARCT) shares soared 8.7% in the last trading session to close at $19.62. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands ...
ARCT-810 could reduce the need for ammonia scavengers and ease the rigid dietary protein restrictions that OTC patients face today, thus improving the quality of life for those with the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results